Sharon O’Byrne

1.3k total citations
27 papers, 498 citations indexed

About

Sharon O’Byrne is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Sharon O’Byrne has authored 27 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 13 papers in Epidemiology and 9 papers in Immunology. Recurrent topics in Sharon O’Byrne's work include Inflammatory Bowel Disease (20 papers), Microscopic Colitis (10 papers) and Cell Adhesion Molecules Research (4 papers). Sharon O’Byrne is often cited by papers focused on Inflammatory Bowel Disease (20 papers), Microscopic Colitis (10 papers) and Cell Adhesion Molecules Research (4 papers). Sharon O’Byrne collaborates with scholars based in United Kingdom, United States and Switzerland. Sharon O’Byrne's co-authors include Mary Keir, Christopher A Lamb, J. Feely, Eugene C. Butcher, Diana Luca, John Mansfield, Jackson G. Egen, Stefan Schreiber, Brian G. Feagan and Meina Tang and has published in prestigious journals such as Circulation, Gastroenterology and Gut.

In The Last Decade

Sharon O’Byrne

25 papers receiving 481 citations

Peers

Sharon O’Byrne
A Etzioni Israel
Jonas Weyler Belgium
Mitsunori Noguchi Japan
Igor Jovanović Serbia
Maria E. Joosse Netherlands
Dekai Qiu China
Leonidas A. Bourikas Greece
André Zonetti de Arruda Leite Brazil
Gary R. Lichtenstein United States
Christine Gouarin France
A Etzioni Israel
Sharon O’Byrne
Citations per year, relative to Sharon O’Byrne Sharon O’Byrne (= 1×) peers A Etzioni

Countries citing papers authored by Sharon O’Byrne

Since Specialization
Citations

This map shows the geographic impact of Sharon O’Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon O’Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon O’Byrne more than expected).

Fields of papers citing papers by Sharon O’Byrne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon O’Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon O’Byrne. The network helps show where Sharon O’Byrne may publish in the future.

Co-authorship network of co-authors of Sharon O’Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon O’Byrne. A scholar is included among the top collaborators of Sharon O’Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon O’Byrne. Sharon O’Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feagan, Brian G., Stefan Schreiber, Douglas C. Wolf, et al.. (2018). Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases. 25(6). 1028–1035. 21 indexed citations
2.
Lamb, Christopher A, Sharon O’Byrne, Mary Keir, & Eugene C. Butcher. (2018). Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 12(suppl_2). S653–S668. 59 indexed citations
3.
Wei, Xiaohui, Leonid Gibiansky, Yehong Wang, et al.. (2017). Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis. The Journal of Clinical Pharmacology. 58(3). 386–398. 6 indexed citations
4.
Vermeire, Séverine, Edward V. Loftus, Jean‐Frédéric Colombel, et al.. (2017). Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study. Gastroenterology. 152(5). S601–S601. 9 indexed citations
5.
Lamb, Christopher A, John Mansfield, Gaik W. Tew, et al.. (2016). αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. Journal of Crohn s and Colitis. 11(5). jjw189–jjw189. 53 indexed citations
6.
O’Byrne, Sharon, et al.. (2016). Discovery of Biomarkers of Response in Early Drug Development. Journal of Crohn s and Colitis. 10(suppl 2). S560–S566. 3 indexed citations
7.
Colombel, Jean‐Frédéric, Íngrid Ordás, Thomas Ullman, et al.. (2015). Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 150(2). 389–395.e3. 34 indexed citations
8.
Fuh, Franklin, Rich Erickson, Romeo Maciuca, et al.. (2015). Etrolizumab Treatment Does Not Modify Levels of VCAM-1 in Ulcerative Colitis Patients. The American Journal of Gastroenterology. 110. S797–S798. 1 indexed citations
9.
O’Byrne, Sharon, Mary Keir, Christopher R. Cabanski, et al.. (2015). Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis. Gastroenterology. 148(4). S–442. 2 indexed citations
10.
Fuh, Franklin, Rich Erickson, Meina Tang, et al.. (2015). Etrolizumab Treatment Modulates MAdCAM-1 Levels in Serum in Ulcerative Colitis Patients. The American Journal of Gastroenterology. 110. S797–S797. 3 indexed citations
11.
12.
Rimola, Jordi, William J. Sandborn, Peter Higgins, et al.. (2014). 995 Feasibility, Precision and Reproducibility of MR Enterography for Detection of Inflammation in Crohn's Disease in a Multicenter Clinical Trial. Gastroenterology. 146(5). S–174. 1 indexed citations
13.
Faubion, William A., Joel G. Fletcher, Sharon O’Byrne, et al.. (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal of Gastroenterology. 108(12). 1891–1900. 82 indexed citations
14.
15.
Rutgeerts, Paul, Richard N. Fedorak, Daan W. Hommes, et al.. (2012). A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut. 62(8). 1122–1130. 111 indexed citations
16.
17.
Rutgeerts, Paul, Richard N. Fedorak, Daniël W. Hommes, et al.. (2011). A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC). Gastroenterology. 140(5). S–125. 6 indexed citations
18.
Lyons, Declan, et al.. (1997). ACE Inhibition. Circulation. 96(3). 911–915. 16 indexed citations
19.
O’Byrne, Sharon, et al.. (1993). Plasma Protein Binding of Lidocaine and Warfarin in Insulin-Dependent and Non-Insulin-Dependent Diabetes Mellitus. Clinical Pharmacokinetics. 24(2). 183–186. 9 indexed citations
20.
O’Byrne, Sharon & J. Feely. (1990). Effects of Drugs on Glucose Tolerance in Non-Insulin-Dependent Diabetics (Part II)1. Drugs. 40(2). 203–219. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Etzioni Breakdown of academic impact, for papers by Jonas Weyler Breakdown of academic impact, for papers by Mitsunori Noguchi Breakdown of academic impact, for papers by Igor Jovanović Breakdown of academic impact, for papers by Maria E. Joosse Breakdown of academic impact, for papers by Dekai Qiu Breakdown of academic impact, for papers by Leonidas A. Bourikas Breakdown of academic impact, for papers by André Zonetti de Arruda Leite Breakdown of academic impact, for papers by Gary R. Lichtenstein Breakdown of academic impact, for papers by Christine Gouarin
Rankless by CCL
2026